We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email :PharmaSources@imsinoexpo.com
Whatsapp :+86-13621645194
Category:Intermediates > Chiral Intermediates Product Name:Aniracetam CAS No.:72432-10-1 Standard:USP Price(USD):0.00 Company:SHANXI YONGJIN GROUP CO LTD
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Monthly Production Capacity: 1000kg
Packaging Information: As required
Sample Provided: yes
Payment Terms: TT/LC
Product Name:Aniracetam
Other Name:1-p-Anisoyl-2-pyrrolidinone丨Draganon丨1-anisoyl-2-pyrrolidinone丨1-(4-Methoxybenzoyl)-2-pyrrolidinone
Molecular Formula:C12H13NO3
Molecular Weight:219.236
Use:Aniracetam(Ro 13-5057) is a nootropics and neuroprotective drug, which is selectively modulates the AMPA receptor and nAChR.Target: AMPA; nAChRAniracetam is an ampakine and nootropic of the racetam chemical class purported to be considerably more potent than piracetam. It selectively modulates the AMPA receptor. It is lipid soluble and has possible cognition enhancing effects. It has been tested in animals extensively, Alzheimer's patients and temporarily-impaired healthy subjects. It has shown potential as an anxiolytic in three clinical animal models [1].Administration of aniracetam for 10 days (post-natal days (PND) 18-27), at a dose of 50 mg/kg reversed cognitive deficits in both rat genders, indicated by a significant increase in the number of avoidances and the number of 'good learners'. After the termination of the nootropic treatment, a significant increase in both amplitude and frequency of AMPA receptor-mediated mEPSCs in hippocampal CA-1 pyramidal cells was observed [2].Clinical indications: Cognitive disorder; StrokeFDA Approved Date: Toxicity: insomnia; headaches; nausea or rash.